To the full analysis
Mediclin stock: growth
MED.DEMediclin reported $869.29M in revenue for fiscal 2025, up 4.8% on the prior year, up 3.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
3.9%
per year from 2006 to 2025, per share 1.7%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
7.3%
per year from 2006 to 2025, per share 5%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 3.5% | 3.5% | 3.9% |
| Revenue per share | 3.5% | 3.5% | 1.7% |
| Earnings | no data | 4.4% | no data |
| Earnings per share | no data | 4.4% | no data |
| Free cash flow | −11.2% | 32.9% | 7.3% |
| Free cash flow per share | −11.2% | 32.9% | 5.0% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $419.41M | $0 | $14.83M |
| 2007 | $434.34M | $6.35M | $18.19M |
| 2008 | $506.17M | $8.06M | −$20.26M |
| 2009 | $521.45M | $11.48M | $14.7M |
| 2010 | $539.83M | $11.19M | −$8.82M |
| 2011 | $546.92M | $3.3M | −$13.18M |
| 2012 | $564.84M | −$1.55M | −$9.51M |
| 2013 | $570.62M | −$2.92M | −$7.4M |
| 2014 | $596.2M | $9.42M | $13.47M |
| 2015 | $615.38M | $18.32M | $3.32M |
| 2016 | $643.08M | $18.33M | $4.15M |
| 2017 | $674.94M | $4.33M | −$18.15M |
| 2018 | $714.84M | $8.55M | −$18.56M |
| 2019 | $745.86M | $10.71M | $27.33M |
| 2020 | $731.24M | −$9.97M | $102.96M |
| 2021 | $745.86M | $1.62M | $71.98M |
| 2022 | $780.88M | $10.46M | $9.55M |
| 2023 | $809.02M | −$11.94M | $44.8M |
| 2024 | $829.75M | $27.52M | $39.75M |
| 2025 | $869.29M | $28.24M | $57M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 25 Apr 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.